NetworkNewsBreaks – Silo Pharma Inc. (SILO) Anno
Post# of 137
(Total Views: 147)
Posted On: 05/19/2022 3:53:13 PM
NetworkNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made in this study, which seeks to examine the effects of psilocybin as an anti-inflammatory agent,” said Eric Weisblum, CEO of Silo Pharma. “We are encouraged by the progress and look forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of these markers when data has been analyzed and completed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s. “Successful dosing and collection of blood samples from enrolled patients is an important milestone that demonstrates the progress being made in this study, which seeks to examine the effects of psilocybin as an anti-inflammatory agent,” said Eric Weisblum, CEO of Silo Pharma. “We are encouraged by the progress and look forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of these markers when data has been analyzed and completed.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)SILO Pharma Inc. (SILO) Stock Research Links
Scroll down for more posts ▼